Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
- 1 June 2006
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1762 (6) , 616-626
- https://doi.org/10.1016/j.bbadis.2006.03.004
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSNeurology, 2005
- Mitochondria take center stage in aging and neurodegenerationAnnals of Neurology, 2005
- Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic miceJournal of Comparative Neurology, 2005
- Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's diseaseExperimental Neurology, 2004
- Experimental therapeutics in transgenic mouse models of Huntington's diseaseNature Reviews Neuroscience, 2004
- Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic miceJournal of Neurochemistry, 2003
- Effects of Coenzyme Q10 in Early Parkinson DiseaseArchives of Neurology, 2002
- Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2002
- A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s diseaseNeurology, 2001
- Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's DiseaseJournal of Neuroscience, 2000